We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B Turnover 32.84%
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-1.03%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$438M
AUM Growth
-$21.2M
Cap. Flow
+$25.3M
Cap. Flow %
5.78%
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11
Avg Time Held
1.4 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$17.2M
2
CYTK icon
Cytokinetics
CYTK
+$12M
3
CRGX icon
CARGO Therapeutics
CRGX
+$10.6M
4
JBIO icon
Jade Biosciences
JBIO
+$8.34M
5
ARVN icon
Arvinas
ARVN
+$7.17M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.83M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.31M
3
CMPX icon
Compass Therapeutics
CMPX
+$6.28M
4
CPRX icon
Catalyst Pharmaceutical
CPRX
+$5.67M
5
NYXH icon
Nyxoah
NYXH
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 98.24%
2 Miscellaneous 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TARA icon
26
Protara Therapeutics
TARA
$139M
$5.3M 1.21%
2,304,262
-388,332
-14% -$1.14M
2019 Q3
19 quarters
NTLA icon
27
Intellia Therapeutics
NTLA
$1.61B
$4.88M 1.11%
218,000
-37,000
-15% -$881K
2023 Q4
2 quarters
NUVL icon
28
DELISTED
Nuvalent
NUVL
$4.5M 1.03%
+59,300
New +$4.22M
2024 Q2
0 quarters
SYRS icon
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.47M 1.02%
865,443
+77,898
+10% +$409K
2023 Q4
2 quarters
LQDA icon
30
Liquidia Corp
LQDA
$3.09B
$3.9M 0.89%
325,000
-70,000
-18% -$929K
2021 Q4
10 quarters
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.43B
$3.64M 0.83%
105,000
-7,700
-7% -$226K
2023 Q4
2 quarters
GOSS icon
32
Gossamer Bio
GOSS
$53.8M
$3.52M 0.8%
48,875
+18,374
+60% +$1.1M
2023 Q2
4 quarters
LXRX icon
33
Lexicon Pharmaceuticals
LXRX
$685M
$3.15M 0.72%
+1,875,000
New +$3.36M
2024 Q2
0 quarters
SVRA icon
34
Savara
SVRA
$927M
$2.88M 0.66%
714,960
-140,040
-16% -$623K
2024 Q1
1 quarter
ALLK icon
35
DELISTED
Allakos
ALLK
$2.78M 0.64%
2,780,000
+345,000
+14% +$410K
2024 Q1
1 quarter
VTYX icon
36
DELISTED
Ventyx Biosciences
VTYX
$2.75M 0.63%
1,190,000
-95,000
-7% -$395K
2023 Q4
2 quarters
VSTM icon
37
Verastem
VSTM
$793M
$2.73M 0.62%
915,000
+703,600
+333% +$5.8M
2023 Q2
4 quarters
RGLS icon
38
DELISTED
Regulus Therapeutics
RGLS
$2.63M 0.6%
1,475,000
+1,304,692
+766% +$3.03M
2024 Q1
1 quarter
LYEL icon
39
Lyell Immunopharma
LYEL
$201M
$2.42M 0.55%
83,500
-84,250
-50% -$4.01M
2024 Q1
1 quarter
RLMD icon
40
Relmada Therapeutics
RLMD
$334M
$1.8M 0.41%
600,000
-159,000
-21% -$575K
2023 Q3
3 quarters
FULC icon
41
Fulcrum Therapeutics
FULC
$279M
$1.77M 0.4%
285,000
+155,000
+119% +$1.17M
2023 Q4
2 quarters
KPTI icon
42
Karyopharm Therapeutics
KPTI
$8.66M
$1.24M 0.28%
+95,000
New +$1.57M
2024 Q2
0 quarters
IBIO icon
43
iBio
IBIO
$49.2M
$791K 0.18%
375,000
-305,000
-45% -$656K
2024 Q1
1 quarter
PMVP icon
44
PMV Pharmaceuticals
PMVP
$65.2M
$770K 0.18%
475,000
+3,519
+0.7% +$6.35K
2024 Q1
1 quarter
JBIO icon
45
Jade Biosciences
JBIO
$863M
$730K 0.17%
+12,571
New +$8.34M
2024 Q2
0 quarters
DSGN icon
46
Design Therapeutics
DSGN
$651M
$687K 0.16%
205,000
+91,962
+81% +$358K
2024 Q1
1 quarter
ABCL icon
47
AbCellera Biologics
ABCL
$3.85B
$592K 0.14%
+200,000
New +$757K
2024 Q2
0 quarters
ALGS icon
48
Aligos Therapeutics
ALGS
$31.2M
$441K 0.1%
50,400
-14,800
-23% -$260K
2023 Q4
2 quarters
OKUR icon
49
OnKure Therapeutics
OKUR
$85M
$249K 0.06%
+16,500
New +$280K
2024 Q2
0 quarters
CMPX icon
50
Compass Therapeutics
CMPX
$159M
– –
-3,170,000
Closed -$6.28M –
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
TFA
Teamwork Financial Advisors San Antonio, Texas $1.1B AUM 39.98% 1-Year Est. Return

Opaleye Management's Q2 2024 Portfolio in Review

As of Q2 2024, Opaleye Management held 62 positions worth $438M, down 4.6% from $459M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management deployed $25.3M of net new capital in Q2 2024, opening 9 new positions and adding to 15 existing holdings. Its largest new stake was Immunome: 1,102,500 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $8.31M trimmed.

  • Opaleye Management's largest Q2 2024 buy was Immunome: 1,102,500 shares worth $13.3M.
  • Opaleye Management added most to Arvinas in Q2 2024, an estimated $7.17M increase.
  • Opaleye Management's biggest Q2 2024 reduction was Ocular Therapeutix, cutting an estimated $8.31M.
  • Opaleye Management fully exited Crinetics Pharmaceuticals in Q2 2024, selling an estimated $9.83M.
  • Opaleye Management's ten largest holdings make up 59% of its $438M portfolio in Q2 2024.
  • Opaleye Management opened 9 new positions and closed 11 in Q2 2024.
  • Opaleye Management's portfolio value fell 4.6% quarter-over-quarter to $438M.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.